257 results on '"Sverre E"'
Search Results
2. Highlights of the 2023 European Society of Hypertension Guidelines: what has changed in the management of hypertension in patients with cardiac diseases?
3. Effect of antihypertensive treatment in isolated systolic hypertension (ISH) – systematic review and meta-analysis of randomised controlled trials
4. Women’s health, cardiovascular risk and hypertension: the perspective still needs to improve
5. Women’s health, cardiovascular risk and hypertension: the perspective still needs to improve
6. Masked hypertension in type 2 diabetes: never take normotension for granted and always assess out-of-office blood pressure
7. TIME to face the reality about evening dosing of antihypertensive drugs in hypertension
8. The five RADIANCE-HTN and SPYRAL-HTN randomised studies suggest that the BP lowering effect of RDN corresponds to the effect of one antihypertensive drug
9. Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified
10. Masked hypertension in type 2 diabetes: never take normotension for granted and always assess out-of-office blood pressure
11. Single-pill combinations, hypertension control and clinical outcomes: potential, pitfalls and solutions
12. Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk
13. Thirty years with LIFE—a randomized clinical trial with more than 200 published articles on clinical aspects of left ventricular hypertrophy
14. Hypertension management during the COVID-19 pandemic: what can we learn for the future?
15. A 30th anniversary and a glimpse of the future
16. Attended vs. unattended blood pressure – learnings beyond SPRINT
17. The five RADIANCE-HTN and SPYRAL-HTN randomised studies suggest that the BP lowering effect of RDN corresponds to the effect of one antihypertensive drug
18. Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers
19. Was it optimal to drop a diuretic as a first-line choice of drug treatment in the 2020 International Society of Hypertension Guidelines?
20. Combining proteomics, home blood pressure telemonitoring and patient empowerment to improve cardiovascular and renal protection
21. Cuff-less measurements of blood pressure: are we ready for a change?
22. Better drug adherence improves blood pressure control and lowers cardiovascular disease outcomes – from single pill combinations to monitoring of a nationwide health insurance database
23. Combining proteomics, home blood pressure telemonitoring and patient empowerment to improve cardiovascular and renal protection
24. Better drug adherence improves blood pressure control and lowers cardiovascular disease outcomes – from single pill combinations to monitoring of a nationwide health insurance database
25. Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension
26. Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk
27. New data on antihypertensive drugs and risk of cancer: should we worry?
28. In memoriam: Jiří Widimský Sr. 1925–2020
29. Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers
30. Challenges in coronary heart disease prevention – experiences from a long-term follow-up study in Norway
31. Was it optimal to drop a diuretic as a first-line choice of drug treatment in the 2020 International Society of Hypertension Guidelines?
32. In memoriam: Peter Sleight 1929–2020
33. The International Society of Hypertension Guidelines 2020 – a new drug treatment recommendation in the wrong direction?
34. Intensive systolic blood pressure control and prevention of new onset atrial fibrillation in the SPRINT study: is the association really controversial?
35. On-treatment HDL cholesterol predicts incident atrial fibrillation in hypertensive patients with left ventricular hypertrophy
36. Blood pressure medication should not be routinely dosed at bedtime. We must disregard the data from the HYGIA project
37. How to deal with the occurrence of rare drug-induced adverse events: the example of sprue-like enteropathy induced by olmesartan medoxomil and other angiotensin-receptor blockers
38. The Health Outcomes Prevention and Evaluation 4 (HOPE 4) project: A successful community-based intervention to lower cardiovascular risk in people with hypertension
39. Systolic blood pressure control prevents cognitive decline and slows development of white matter lesions in the brain: the SPRINT MIND study outcomes
40. The Health Outcomes Prevention and Evaluation 4 (HOPE 4) project: A successful community-based intervention to lower cardiovascular risk in people with hypertension
41. Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets
42. Relationship between abnormal P-wave terminal force in lead V1 and left ventricular diastolic dysfunction in hypertensive patients: the LIFE study
43. The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease
44. Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial
45. The SPRINT study: Outcome may be driven by difference in diuretic treatment demasking heart failure and study design may support systolic blood pressure target below 140 mmHg rather than below 120 mmHg
46. Need for multiple risk reduction strategies in clinical trials enrolling high risk patients - FOURIER investigating PCSK-9 inhibitor to lower cholesterol revisited
47. The PARAGON-Heart failure trial – another disappointment for heart failure patients with hypertension and preserved ejection fraction
48. Antihypertensive therapy prevents new-onset atrial fibrillation in patients with isolated systolic hypertension: the LIFE study
49. The PARAGON Heart Failure trial – ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction
50. Need for multiple risk reduction strategies in clinical trials enrolling high risk patients - FOURIER investigating PCSK-9 inhibitor to lower cholesterol revisited
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.